Hospira Issues A Voluntary Nationwide Recall Of One Lot Of 1% Lidocaine HCL Injection Due To The Presence Of Dark Particulate

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Hospira Issues A Voluntary Nationwide Recall Of One Lot Of 1% Lidocaine HCL Injection Due To The Presence Of Dark Particulate

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Issues A Voluntary Nationwide Recall Of One Lot Of 1% Lidocaine HCL Injection Due To The Presence Of Dark Particulate

10/04/2013 07:39 PM EDT

Hospira, Inc.(NYSE: HSP), announced today it has initiated a voluntary nationwide recall of one lot of 1% Lidocaine HCI Injection, USP, 10 mg/mL, 20 mL Multiple-dose Fliptop Vial, NDC 0409-4276-01 Lot 25-090-DK (the lot number may be followed by 01 or 02).

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420